Purchase this article with an account.
Joao J Nassaralla, Arthur A Nassaralla, Miguel Hage Amaro, Joao J Nassaralla; Ranibizumab or Aflibercept Therapy with Dexamethosone Intravitreal Injection Efficacy in Diabetic Macular Edema.. Invest. Ophthalmol. Vis. Sci. 2018;59(9):192.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Evaluate the macular thickness and visual acuity after the treatment with aflibercept or ranibizumab with dexamethasone intravitreal injection
Four groups randomly selected and submitted to alternating treatment with aflibercept (G1), ranibizumab (G2), aflibercept with dexamethasone (G3) and ranibizumab with dexamethasone (G4). A randomized clinical trial was conducted in 12 patients, diagnosed with diabetic macular edema from January 2017 to October 2017, in order to evaluate and compare the efficacy of this disease according to visual acuity and macular thickness.Were performed 3 intravitreal applications of anti-vgf, with one application per month in G1 e G2. In G3 and G4 was made dexamethasone with first anti-vegf injection.We monitoring with Optical Coherence Tomography on days 7 and 30 subsequent to applications.
Was observed in patients subjected the applications of aflibercept with dexamethasone (G3) or ranibizumab with dexamethasone (G4) application there was a diabetic macular edema reduction of about 52.32% one week after the third injection of antiangiogenic injection, being superior to the other groups (aflibercept or ranibizumab). Was similar to the reduction observed with the application of G1 or G2 in which it was observed 30.82% and 32.23% reduction in edema.The visual acuity observed a constant improvement in the 4 groups, two lines in G1 and G2, but 4 lines in G3 and G4 (according to the scale of Snellen).
We can state through this study that the treatment of diabetic macular edema with anti-vegf associate with corticosteroid has a greater benefit than the treatment with these drugs alone, shown by optical coherence tomography.Visual acuity increased with the association of drugs regardless of which antiangiogenic drug was used
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only